REOPRO (Eli Lilly and Company)
Welcome to the PulseAid listing for the REOPRO drug offered from Eli Lilly and Company. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Eli Lilly and Company |
| NON-PROPRIETARY NAME: | abciximab |
| SUBSTANCE NAME: | ABCIXIMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 1993-12-16 |
| END MARKETING DATE: | 0000-00-00 |
REOPRO HUMAN PRESCRIPTION DRUG Details:
| Item Description | REOPRO from Eli Lilly and Company |
| LABELER NAME: | Eli Lilly and Company |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 2(mg/mL) |
| START MARKETING DATE: | 1993-12-16 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0002-7140_a667f669-cd7e-4dc0-89b7-9be550b03b3c |
| PRODUCT NDC: | 0002-7140 |
| APPLICATION NUMBER: | BLA103575 |
Other ABCIXIMAB Pharmaceutical Manufacturers / Labelers:
